- Lähetä linkki
- RSS
- google +
- Tulostusversio
- Lähetä tämä sivu
Uutisia (Harvinaiset sairaudet)
Terveys-EU-sivuston uutis- ja tapahtumasyötteet tuotetaan automaattisesti Euroopan komission määrittelemien kriteerien mukaisesti. Luokitteluvirheet ovat mahdollisia.
Preparing the way for the understanding of a rare neurological disease » europa.eu
ENRAH-SME was a pioneering European Union (EU)-funded project which laid the crucial groundwork for a major breakthrough in the understanding and potential treatment of a rare childhood neurological [...]Moving closer to personalised medication for complex diseases» europa.eu
There are some problems that are more complicated than others, and some problems that are more common than others. Unfortunately, when it comes to disease, complex diseases are also the most common o[...]RareConnect announces 40th online community»
RareConnect.org, the platform created, monitored and run by patient organisations EURORDIS and NORD, continues its mission of bringing rare disease patients together, across borders and beyond language barriers
RARE-Bestpractices: Researching rare diseases» europa.eu
Clinical research needs to optimise its agenda by taking into consideration both patients' and clinicians' needs and interests. This is the goal of a four-year project funded by the EU's Seventh Fram[...]28 February 2013 - Rare Disease Day: 'Rare disorders without borders' » europa.eu
The European Medicines Agency supports Rare Disease Day, which is taking place on Thursday 28 February.[...]EU provides €144 million for new research on rare diseases» europa.eu
European Commission Press release Brussels, 28 February 2013 The European Commission has today, on Rare Disease Day 2013, announced €144 million of new funding for 26 research projects on rare diseas[...]Q&A on 26 new EU research projects on rare diseases» europa.eu
European Commission MEMO Brussels, 28 February 2013 1) Why is research at European level important? There is a huge need for European cooperation in rare diseases research. Individual Member States a[...]European Medicines Agency revises three guidance documents to include orphan-related information» europa.eu
The European Medicines Agency has revised three guidance documents to include information related to orphan medicines.[...]Regulatory and procedural guideline: Standard acute-myeloid-leukaemia paediatric investigation plan, draft: consultation open» europa.eu
The standard PIP for acute myeloid leukaemia (AML) was prepared by the Paediatric Committee with external experts in the Paediatric oncology task force of the EMA. The aim is to highlight the persist[...]European Medicines Agency: Committee for Orphan Medicinal Products – strengthened interactions with patients and international partners»
"The European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) is stepping into another stage of its role in the lifecycle of orphan medicines and in the field of rare diseases, after the first 12 years of the implementation of the Orphan-Medicinal-Product Regulation in the European Union," explains Bruno Sepodes, chair of the COMP